Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis

被引:16
作者
Prica, Anca [1 ]
Chan, Kelvin [2 ,3 ]
Cheung, Matthew C. [1 ]
机构
[1] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Haematol, Dept Med, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Med Oncol, Dept Med, Toronto, ON M4N 3M5, Canada
[3] Univ Toronto, Princess Margaret Hosp, Toronto, ON M4N 3M5, Canada
关键词
decision analysis; methotrexate; lymphoma; central nervous system; quality of life; radiotherapy; PRIMARY CNS LYMPHOMA; HIGH-DOSE METHOTREXATE; WHOLE-BRAIN RADIOTHERAPY; QUALITY-OF-LIFE; DEFERRED RADIOTHERAPY; PHASE-II; EUROPEAN ORGANIZATION; INITIAL TREATMENT; RADIATION; SALVAGE;
D O I
10.1111/j.1365-2141.2012.09208.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In immunocompetent patients with primary central nervous system (CNS) lymphoma, combined modality therapy (CMT) using high-dose methotrexate and whole brain radiotherapy has improved response rates compared to chemotherapy alone. The trade-off is delayed and potentially devastating treatment-related neurotoxicity. A Markov decision-analytic model compared CMT to chemotherapy alone in patients with primary CNS lymphoma. Baseline probabilities were derived from a systematic literature review. Outcomes were life expectancy and quality-adjusted life expectancy. Sensitivity analyses were performed. The life expectancy was 2.69 years for CMT and 2.77years for chemotherapy alone. The quality-adjusted life expectancies for the two strategies were 1.70 and 1.67 quality-adjusted life years (QALYs) respectively. In younger patients <60 years of age, CMT yielded a quality-adjusted life expectancy of 2.71 QALYs, compared to 2.09 QALYs for chemotherapy alone, yielding an expected benefit with CMT of 0.62 QALYs or 7.4 quality-adjusted months. There was no difference between the strategies in the older group. The model was robust to key variables for the younger group. The preferred induction strategy for younger patients appears to be CMT, maximizing life expectancy, and QALYs. This analysis confirms that the preferred strategy for older patients is chemotherapy alone.
引用
收藏
页码:600 / 607
页数:8
相关论文
共 27 条
  • [11] Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
    Gavrilovic, Igor T.
    Hormigo, Adilia
    Yahalom, Joachim
    DeAngelis, Lisa M.
    Abrey, Lauren E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) : 4570 - 4574
  • [12] High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma
    Gerard, Lauren M.
    Imrie, Kevin R.
    Mangel, Joy
    Buckstein, Rena
    Doherty, Mary
    Mackenzie, Robert
    Cheung, Matthew C.
    [J]. LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1882 - 1890
  • [13] PREIRRADIATION METHOTREXATE CHEMOTHERAPY OF PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - LONG-TERM OUTCOME
    GLASS, J
    GRUBER, ML
    CHER, L
    HOCHBERG, FH
    [J]. JOURNAL OF NEUROSURGERY, 1994, 81 (02) : 188 - 195
  • [14] Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients
    Guha-Thakurta, N
    Damek, D
    Pollack, C
    Hochberg, FH
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1999, 43 (03) : 259 - 268
  • [15] Cognitive status and quality of life after treatment for primary CNS lymphoma
    Harder, H
    Holtel, H
    Bromberg, JEC
    Poortmans, P
    Haaxma-Reiche, H
    Kluin-Nelemans, HC
    Menten, J
    van den Bent, MJ
    [J]. NEUROLOGY, 2004, 62 (04) : 544 - 547
  • [16] NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma:: Final report
    Herrlinger, U
    Küker, W
    Uhl, M
    Blaicher, HP
    Karnath, HO
    Kanz, L
    Bamberg, M
    Weller, M
    [J]. ANNALS OF NEUROLOGY, 2005, 57 (06) : 843 - 847
  • [17] Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: A multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group
    Hoang-Xuan, K
    Taillandier, L
    Chinot, O
    Soubeyran, P
    Bogdhan, U
    Hildebrand, J
    Frenay, M
    De Beule, N
    Delattre, JY
    Baron, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2726 - 2731
  • [18] Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma
    Hottinger, Andreas F.
    DeAngelis, Lisa M.
    Yahalom, Joachim
    Abrey, Lauren E.
    [J]. NEUROLOGY, 2007, 69 (11) : 1178 - 1182
  • [19] Marcus R, 2007, GUIDELINES DIAGNOSIS
  • [20] Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma
    Nguyen, PL
    Chakravarti, A
    Finkelstein, DM
    Hochberg, FH
    Batchelor, TT
    Loeffler, JS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) : 1507 - 1513